Iovance Biotherapeutics, Inc.
IOVAIovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Drugs in Pipeline
8
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Lifileucel plus Pembrolizumab
Metastatic Melanoma
Pembrolizumab
Metastatic Melanoma
IOV-3001
Unresectable Melanoma
IOV-2001
Chronic Lymphocytic Leukemia
LN-145-S1
Squamous Cell Carcinoma of the Head and Neck
Lifileucel
Endometrial Cancer
LN-145
Metastatic Non Small Cell Lung Cancer
IOV-4001
Unresectable Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lifileucel plus Pembrolizumab | Phase 3 | Metastatic Melanoma | - | - |
Pembrolizumab | Phase 2 | Metastatic Melanoma | - | - |
IOV-3001 | Phase 2 | Unresectable Melanoma | - | - |
IOV-2001 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
LN-145-S1 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Lifileucel | Phase 2 | Endometrial Cancer | - | - |
LN-145 | Phase 2 | Metastatic Non Small Cell Lung Cancer | - | - |
IOV-4001 | Phase 2 | Unresectable Melanoma | - | - |
Metastatic Melanoma
2 drugs in this indication
Unresectable Melanoma
2 drugs in this indication
Chronic Lymphocytic Leukemia
1 drug in this indication
Squamous Cell Carcinoma of the Head and Neck
1 drug in this indication
Endometrial Cancer
1 drug in this indication
Metastatic Non Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)